A2A along with LAXAI to co-develop SARS-CoV-2 main proteases inhibitors

▴ a2a-laxai-collaborates-codeveloping-sarscov2-main-proteases-inhibitors
With this collaboration, A2A wants to discover highly selective targeted inhibitors of SARS-CoV-2 MPro

A2A Pharmaceuticals, a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents announces today an agreement to co-develop SARS-CoV-2 Main Proteases inhibitors for the treatment of COVID-19 with Laxai Life Sciences Pvt Ltd, a company delivering cutting edge technological and scientific and development solutions

Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform SCULP, which are currently being synthesized and will be evaluated by Laxai. Both parties will collaborate in preclinical optimization and selection of lead candidates to enter the clinic.

"MPro is a very attractive drug target for COVID-19 due to its pivotal role in mediating viral replication and transcription as well as its druggability owing to a well-defined pocket and susceptibility to targeted covalent inhibitors demonstrated in recent structural information", said Dr. Elena Diez Cecilia, program lead and director of BD and R&D strategy for A2A. She added "We're excited to embark on this collaboration with Laxai, combining our drug design expertise with Laxai's vast drug discovery experience including chemical process R&D and GMP manufacturing. Combined, we are positioned to accelerate development to reach patients faster"

With this collaboration, A2A wants to put its technology and expertise to use to discover highly selective targeted inhibitors of SARS-CoV-2 MPro, as opposed to repurposing or vHTS efforts ongoing elsewhere, to design more efficacious and safer treatments.

Dr. Ram S. Upadhayaya, CEO Laxai Life Sciences, commented, "We are excited to collaborate with A2A on COVID-19 project. Laxai's in-house technological capabilities truly compliments its intellectual prowess. This collaboration is an amalgamation of ahead-of-times thoughts; and the product can only be success!"

Dr. Raghava Reddy Kethiri, CSO Laxai Life Sciences, says, "the designed compounds have the potential to have broad-spectrum antiviral activity owing to the conserved active site residues of Mpro among multiple viruses in the supercluster, which includes coronaviruses and other related viruses that could emerge in future."

Tags : #A2APharmacuetical #LaxaiLifeSciences #ProteasesInhibitor #Coronavirus #Hyderabad

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024